BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30794795)

  • 1. Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration.
    Feng B; West M; Patel NC; Wager T; Hou X; Johnson J; Tremaine L; Liras J
    J Pharm Sci; 2019 Jul; 108(7):2476-2483. PubMed ID: 30794795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
    Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier.
    Colclough N; Alluri RV; Tucker JW; Gozalpour E; Li D; Du H; Li W; Harlfinger S; O'Neill DJ; Sproat GG; Chen K; Yan Y; McGinnity DF
    Drug Metab Dispos; 2024 Jan; 52(2):95-105. PubMed ID: 38071533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using in vitro efflux activities.
    Sato S; Tohyama K; Kosugi Y
    Eur J Pharm Sci; 2020 Jan; 142():105119. PubMed ID: 31682973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding the Efflux In Vitro Assay Toolbox: A CRISPR-Cas9 Edited MDCK Cell Line with Human BCRP and Completely Lacking Canine MDR1.
    Wegler C; Gazit M; Issa K; Subramaniam S; Artursson P; Karlgren M
    J Pharm Sci; 2021 Jan; 110(1):388-396. PubMed ID: 33007277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
    Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
    J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
    Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
    Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
    Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
    Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue Targeting.
    Patel NC; Feng B; Hou X; West MA; Trapa PE; Sciabola S; Verhoest P; Liras JL; Maurer TS; Wager TT
    ACS Chem Neurosci; 2021 Mar; 12(6):1007-1017. PubMed ID: 33651587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
    Marchetti S; Oostendorp RL; Pluim D; van Eijndhoven M; van Tellingen O; Schinkel AH; Versace R; Beijnen JH; Mazzanti R; Schellens JH
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3307-13. PubMed ID: 18089724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.
    Reznicek J; Ceckova M; Ptackova Z; Martinec O; Tupova L; Cerveny L; Staud F
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration.
    Gonçalves J; Silva S; Gouveia F; Bicker J; Falcão A; Alves G; Fortuna A
    Int J Pharm; 2021 Jan; 593():120161. PubMed ID: 33307160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
    Wang J; Gan C; Retmana IA; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
    Int J Pharm; 2019 Feb; 556():172-180. PubMed ID: 30553002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Utility of Canine Mdr1 Knockout Madin-Darby Canine Kidney I Cells in Permeability Screening and Efflux Substrate Determination.
    Chen EC; Broccatelli F; Plise E; Chen B; Liu L; Cheong J; Zhang S; Jorski J; Gaffney K; Umemoto KK; Salphati L
    Mol Pharm; 2018 Nov; 15(11):5103-5113. PubMed ID: 30222362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
    Mukkavilli R; Jadhav G; Vangala S
    Curr Pharm Biotechnol; 2017; 18(14):1151-1158. PubMed ID: 29521222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of a high-resolution in vitro human MDR1-MDCK assay and in vivo studies in preclinical species to improve prediction of CNS drug penetration.
    Jiang L; Kumar S; Nuechterlein M; Reyes M; Tran D; Cabebe C; Chiang P; Reynolds J; Carrier S; Sun Y; Eddershaw P; Hay T; Chen W; Feng B
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00932. PubMed ID: 35156331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between Membrane Protein Expression Levels and Transcellular Transport Activity for Breast Cancer Resistance Protein.
    Liu H; Huang L; Li Y; Fu T; Sun X; Zhang YY; Gao R; Chen Q; Zhang W; Sahi J; Summerfield S; Dong K
    Drug Metab Dispos; 2017 May; 45(5):449-456. PubMed ID: 28209803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants.
    Jacqueroux E; Mercier C; Margelidon-Cozzolino V; Hodin S; Bertoletti L; Delavenne X
    Fundam Clin Pharmacol; 2020 Feb; 34(1):109-119. PubMed ID: 31411766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
    Chen X; Unadkat JD; Mao Q
    Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-
    Bicker J; Fortuna A; Alves G; Soares-da-Silva P; Falcão A
    Drug Metab Dispos; 2017 Dec; 45(12):1282-1291. PubMed ID: 28916530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.